Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement

Leuk Lymphoma. 2017 Apr;58(4):996-998. doi: 10.1080/10428194.2016.1222375. Epub 2016 Aug 25.

Authors

Kah-Lok Chan¹, Carrie van der Weyden¹, Christine Khoo², Stephen Lade², Piers Blombery¹, David Westerman^{1

3}, Amit Khot¹, Brian Melo⁴, Ricky W Johnstone^{3

5}, H Miles Prince^{1

3}, Michael Dickinson¹

Affiliations

¹ a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Victoria , Australia.
² b Department of Anatomical Pathology , Peter MacCallum Cancer Centre , Melbourne , Victoria , Australia.
³ c The Sir Peter MacCallum Department of Oncology , The University of Melbourne, Melbourne , Melbourne , Victoria , Australia.
⁴ d Celgene Corporation , Summit , NJ , USA.
⁵ e Peter MacCallum Cancer Centre, Cancer Therapeutics Program , Melbourne , Victoria , Australia.

PMID: 27558082
DOI: 10.1080/10428194.2016.1222375

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibiotics, Antineoplastic / therapeutic use*
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Central Nervous System Neoplasms / diagnosis
Central Nervous System Neoplasms / drug therapy*
Central Nervous System Neoplasms / secondary*
Cyclophosphamide / therapeutic use
Depsipeptides / therapeutic use*
Doxorubicin / therapeutic use
Drug Resistance, Neoplasm
Female
Hematopoietic Stem Cell Transplantation
Humans
Immunophenotyping
Lymphoma, T-Cell, Peripheral / diagnosis
Lymphoma, T-Cell, Peripheral / pathology*
Lymphoma, T-Cell, Peripheral / therapy
Middle Aged
Prednisone / therapeutic use
Remission Induction
Retreatment
Rituximab
Transplantation, Autologous
Treatment Outcome
Vincristine / therapeutic use

Substances

Antibiotics, Antineoplastic
Antibodies, Monoclonal, Murine-Derived
Depsipeptides
R-CHOP protocol
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
romidepsin
Prednisone